Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market opportunities Sabine Häussermann transitions to newly created role of Chief Scientific Officer to drive company’s scientific evidence development initiatives Munich (Germany) and Boston, MA USA, February 18, 2025 – VisionHealth GmbH, a pioneer...
VisionHealth raises 3 million Euro to finance extended COPD and asthma study for market preparation of Kata®, an innovative digital therapeutic for improved inhalation DB Speciality Invest, an investment firm of Dr. Dietrich Bruchmann, invests in VisionHealth Funds will be used for EU and U.S. regulatory approval and commercial launch...
Nagarjun Anantha Padmanabha has been part of the VisionHealth team for four years. As Head of Software Development, he has a lot of responsibilities and a varied scope of duties. This includes, but is not limited to, organizing and leading development teams in the creation of software products, planning, scheduling,...
VisionHealth’s Kata® Clinical to be included into Alcedis service platform for clinical studies Kata® Clinical app supports clinical trials in the field of chronic lung diseases and can be customized to each trial’s individual requirements Based on artificial intelligence (AI), Kata® Clinical can improve both study outcomes and participants’ experience Munich...
VisionHealth receives EU Medical Device Regulation certification VisionHealth is among the first app manufacturers to receive EU Medical Device Regulations (MDR) certification MDR certification prerequisite to enhance, further develop and release future Kata® versions Next Kata® app version will be a CE marked class IIa medical device (MDR) Munich (Germany), December...
VisionHealth's Kata® Clinical app to support sterna biologicals' clinical Phase Ila asthma trial Kata® Clinical app supports Phase Ila proof-of-concept study investigating sterna biologicals' lead compound SB010 in moderate to severe asthma patients Kata® Clinical will be used to enhance inhaler device handling and therapy adherence, reduce drop-out rates and...
VisionHealth adds Clinical Trial Function to Kata® App supporting and optimizing inhalation therapy of chronic lung diseases Kata® Clinical, the new specialized version of Kata® offers clinical trial specific extended functionality Kata® Clinical can be customized to partners’ needs; options include data management and result validation, patient management, inhalation training and monitoring, recording...
Inhalation 2.0 – Knowing what enters the lungs The German Aerosol Therapy Symposium (DATS) will enter its 22nd round on November 6-7, 2020, but this time not in a familiar way. The DATS team has decided to offer the symposium as a hybrid event for the first time due to the latest...
VisionHealth raises 1.5 million Euro for DiGA pivotal study and market preparation of inhalation therapy app Kata® Consortium of existing shareholders supports financing and welcomes two new investors Funds will be used for regulatory approval and commercial launch of the Kata® app in Germany Garching (Germany), February 26, 2021 – VisionHealth GmbH,...
VisionHealth and major regional insurer AOK Bayern to start pilot on Kata® digital health app for severe asthma and COPD supporting inhalation therapy Innovative digital healthcare app Kata® available for the first time to patients covered by statutory health insurance With Kata®, Bavaria’s largest statutory health insurance fund can provide...
